Richard F. Lamb
Studied how amino acids and growth signals reach mTOR, including the IRS feedback loop and nutrient signalling through MAP4K3
Institute of Cancer Research, London (2004) · University of Alberta (2010)
Richard Lamb led the laboratory at the Institute of Cancer Research in London where HAR2004 was done, and Greg Findlay's PhD on new components of the mTOR pathway was carried out under his supervision. By 2010 he was at the University of Alberta, where his group reported that amino acids reach mTOR partly through the kinase MAP4K3, which is held in check by the phosphatase PP2A-T61ε.
In the Atlas he is senior author of HAR2004, which showed that loss of TSC1-2 keeps S6K1 active and that S6K1 then shuts down IRS-1, weakening the cell's insulin-PI3K response. This negative feedback loop is one reason that drugs blocking mTORC1 can end up switching Akt back on.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2004 | M | The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins HAR2004 Senior author: TSC1-2 loss drives S6K1-mediated suppression of IRS-1, establishing mTORC1 negative feedback onto insulin-PI3K signalling (cells). |
Co-authors in the Atlas
People with a profile here who share at least one study with Richard F. Lamb.
- Greg M. Findlay Uses pluripotent stem cells to study how faulty signalling by protein kinases causes intellectual disability
- Laura S. Harrington First author of the 2004 study showing that TSC1-2 loss blunts insulin signalling through S6K1-driven feedback on IRS proteins
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.